Crystalline C-UVC Inactivation of Airborne Microorganisms | Aerobiotix

Crystalline UV-C Inactivation of Airborne Microorganisms: Clinical and Laboratory Analysis of a Novel Germicidal Air Recirculation Technology

Sue Barnes, RN, CIC, FAPIC
Viktoriya Rybalko, M.S, Ph.D.

Study Aims and Design

Hospital acquired infections (HAI) are the number four cause of death in the United States at an annual cost estimated at $40 billion. With emerging scientific data regarding the contribution of air contamination to surgical site infections (SSI), there is increased interest in considering innovative adjunctive technologies to support best air quality in operating rooms (ORs).The study was designed to test the effectiveness of the novel AEROBIOTIX (ABX) crystalline ultraviolet (C-UVC) germicidal irradiation inroom air disinfection and filtration technology on reducing airborne particle contamination in the OR. Single-pass laboratory-based tests were performed to evaluate inactivation efficiency of ABX C-UVC reaction chamber on aerosolized bacteria, viruses and spores. Clinical field tests were carried out to assess the efficacy of C-UVC air recirculation/filtration device on reduction of airborne colony forming units (CFU) and viable particle counts (VPC) in the OR.


C-UVC device is highly efficient in inactivating a broad spectrum of aerosolized microorganisms
The ABX C-UVC system was developed to maximize UV-C dosage required for full inactivation of airborne pathogens while maintaining a high air flow volume of 450 CFM. Laboratory-based in-duct tests were carried out to measure microorganism survival rate after a single-pass exposure to the device CUVC reaction chamber (Figure 2A/B). The calculation of the test organism survival rate was based on the ratio of the downstream to upstream organism counts. All sampled were collected for 10 seconds upstream and 1 minute downstream (n=6 for each location per microorganism tested). Results showed over 99.9% inactivation efficiency of B.atrophaeus, S. epidermidis and MS2 virus test microorganisms during a single-pass test (Figure 2C) confirming highly biocidal property of C-UVC chamber design.

C-UVC air recirculation device installed in the active OR setting is highly effective in reducing airborne bioburden
To evaluate the effectiveness of the C-UVC air recirculation device in the clinical operating room setting ABX C-UVC units were installed in an active OR with standard positive-pressure ventilation. The supply room in sterile instrument processing area was designated as clean area and utilized as an environmental setting control for comparison purposes.
Quantifications of viable airborne microorganisms were performed with C-UVC device in place. Samples were taken over the 4-hour period with device turned OFF (BASELINE) and ON (C-UVC). Two surrogate measures of microbial air contamination were used to evaluate air quality, the colony-forming units (CFU/m³) and viable particle counts (VPC/m³) respectively. During baseline condition in the OR (deviceoff; no C-UVC) the average bacterial counts were at 39 CFU/m³. Deployment of the C-UVC device produced significant decrease in air microbial burden as evidenced by sharp reduction in airborne bacteria counts to 7 CFU/m³ (= 82% reduction) (Figure 3). As expected, no improvement in bacterial counts was seen in the sterile processing area supply room due to initially low bacterial levels detected during baseline period (11 CFU/m³).

Reach Us

444 Alexandersville Rd
Miamisburg, Ohio 45342
+1 888 978 7087

Reach Us

350 Fame Road
West Carrollton, Ohio 45449 USA
+1 888 978 7087



Sr. Vice President of Global Sales and Marketing

Jason leads our global sales team and brings over 18 years of Medical Device experience to Aerobiotix. Jason has led top performing National and Regional Sales teams, selling disruptive technology in the Cardiovascular space with Getinge, Surgical Robotics at Hansen Medical and most recently in the Biologics space with Axogen. Jason received his Bachelor of Science Degree from the University of Indianapolis.



Vice President of Global Marketing

Melissa Gietzen, MBA is a highly skilled strategic marketing professional with over 20 years’ experience in the healthcare industry. She has significant expertise in strategic planning, capital budgeting, service improvement projects, and creating strong successful brands in the orthopedic, cardiac & ophthalmology markets. Melissa holds a undergraduate degree in Management and Organization Development and a masters degree in Business Administration.



President and CEO

The founder and CEO is David Kirschman, M.D., a former physician with extensive experience as CEO, Director, Chief Scientific Officer and operator in the orthopedic and biologic medical device space. Dr. Kirschman holds 55 issued US Patents for a wide range of medical devices. He received his BS in Biological Science cum laude from Colorado State University and M.D. from University of Colorado School of Medicine.

GREGORY CARROLL PH.D. Director Scientific Affairs


Director Scientific Affairs

Dr. Carroll has extensive experience in ultraviolet and photonic science. Prior to joining Aerobiotix, he led the research and development group at Sunstar Engineering. He has a Ph.D. in chemistry from Columbia University and did his postdoctoral fellowship under Nobel laureate Prof. Ben Feringa at the University of Groningen, Netherlands, and Lawrence Berkeley National Laboratory.

TONY EMBREE Chief Commercial Officer


Chief Commercial Officer

Tony leads our global sales organization and commercialization strategy. Prior joining Aerobiotix, he was Senior Manager of Strategy at Stryker. He has led sales and marketing teams in multiple organizations including SurgiCount Medical, part of Patient Safety Technologies, INC (PSTX) as it expanded from 8 hospitals in 2008 to user base of 330 hospitals at time of acquisition in 2013.

COURTNEY ADAMS, Ph.D. VP of Clinical and Medical Affairs


VP of Clinical and Medical Affairs

Dr. Adams leads our global clinical research and education initiatives as well as developing key opinion leaders to support our clinical mission. Prior to joining Aerobiotix, she held leading research and medical affairs roles at Biogen, Axogen, and MedPace. Dr. Adams holds Ph.D. in Pharmacology from University of Cincinnati.

ANTHONY DEFALCO Vice President of Engineering


Vice President of Engineering

Anthony is a topflight medical device product development engineer and leader, experienced in the development and implementation of orthopedic, environmental, and electromechanical systems.

NATHAN UTZ Vice President of Client Services


Vice President of Strategic Accounts

Nathan brings a high level of commitment to servicing and building client relations. Nathan has previously held leadership roles in the medical device industry.

MICHAEL SCHMITZ Chief Financial Officer


Chief Financial Officer

Mr. Schmitz is a highly experienced financial practitioner with financial leadership roles in diverse industries including manufacturing and technology as well as a background in public accounting. He received his BS in accounting, cum laude, from the Miami University of Ohio. Mr. Schmitz is a certified public accountant and certified management accountant.